Skip to main content
AAN.com
Article
September 5, 2018
Letter to the Editor

BOLD cerebrovascular reactivity as a novel marker for crossed cerebellar diaschisis

October 2, 2018 issue
91 (14) e1328-e1337

Abstract

Objective

To study blood oxygen level–dependent cerebrovascular reactivity (BOLD-CVR) as a surrogate imaging marker for crossed cerebellar diaschisis (CCD).

Methods

Twenty-five participants with symptomatic unilateral cerebrovascular steno-occlusive disease underwent a BOLD-CVR and an acetazolamide challenged (15O)-H2O-PET study. CCD and cerebellar asymmetry index were determined from PET and compared to BOLD-CVR quantitative values. Neurologic status at admission and outcome after 3 months were determined with NIH Stroke Scale (NIHSS) and modified Rankin Scale (mRS) scores.

Results

For both the BOLD-CVR and PET examination, a significant cerebellar asymmetry index was found for participants exhibiting CCD (CCD+ vs CCD−: for BOLD-CVR 13.11 ± 9.46 vs 1.52 ± 4.97, p < 0.001; and for PET 7.31 ± 2.75 vs 1.68 ± 2.98, p < 0.001). The area under the curve for BOLD-CVR was 0.89 (95% confidence interval: 0.75–1.0) with 0.91 sensitivity and 0.81 specificity to detect CCD. Participants exhibiting CCD were in poorer clinical condition at baseline (CCD+ vs CCD−: NIHSS 7 vs 1, p = 0.003; mRS 3 vs 1, p = 0.001) and after 3-month follow-up (NIHSS 2 vs 0, p = 0.02; mRS 1 vs 0, p = 0.04). Worse performance on both scores showed an agreement with a larger BOLD-CVR cerebellar asymmetry index. This was not found for PET.

Conclusions

BOLD-CVR demonstrates similar sensitivity to detect CCD as compared to (15O)-H2O-PET in patients with symptomatic unilateral cerebrovascular steno-occlusive disease. Furthermore, participants exhibiting CCD had a poorer baseline neurologic performance and neurologic outcome at 3 months.

Classification of evidence

This study provides Class II evidence that BOLD-CVR identifies CCD in patients with symptomatic unilateral cerebrovascular steno-occlusive disease.

Get full access to this article

View all available purchase options and get full access to this article.

Publication history

Received by Neurology March 1, 2018. Accepted in final form July 2, 2018.

References

1.
Takasawa M, Watanabe M, Yamamoto S, et al. Prognostic value of subacute crossed cerebellar diaschisis: single-photon emission CT study in patients with middle cerebral artery territory infarct. AJNR Am J Neuroradiol 2002;23:189–193.
2.
Sobesky J, Thiel A, Ghaemi M, et al. Crossed cerebellar diaschisis in acute human stroke: a PET study of serial changes and response to supratentorial reperfusion. J Cereb Blood Flow Metab 2005;25:1685–1691.
3.
Pantano P, Baron JC, Samson Y, Bousser MG, Derouesne C, Comar D. Crossed cerebellar diaschisis: further studies. Brain 1986;109(pt 4):677–694.
4.
De Reuck J, Decoo D, Lemahieu I, Strijckmans K, Goethals P, Van Maele G. Crossed cerebellar diaschisis after middle cerebral artery infarction. Clin Neurol Neurosurg 1997;99:11–16.
5.
Kim SE, Choi CW, Yoon BW, et al. Crossed-cerebellar diaschisis in cerebral infarction: technetium-99m-HMPAO SPECT and MRI. J Nucl Med 1997;38:14–19.
6.
Kamouchi M, Fujishima M, Saku Y, Ibayashi S, Iida M. Crossed cerebellar hypoperfusion in hyperacute ischemic stroke. J Neurol Sci 2004;225:65–69.
7.
Komaba Y, Mishina M, Utsumi K, Katayama Y, Kobayashi S, Mori O. Crossed cerebellar diaschisis in patients with cortical infarction: logistic regression analysis to control for confounding effects. Stroke 2004;35:472–476.
8.
Liu Y, Karonen JO, Nuutinen J, Vanninen E, Kuikka JT, Vanninen RL. Crossed cerebellar diaschisis in acute ischemic stroke: a study with serial SPECT and MRI. J Cereb Blood Flow Metab 2007;27:1724–1732.
9.
Baron JC, Bousser MG, Comar D, Castaigne P. “Crossed cerebellar diaschisis” in human supratentorial brain infarction. Trans Am Neurol Assoc 1981;105:459–461.
10.
Yamada H, Koshimoto Y, Sadato N, et al. Crossed cerebellar diaschisis: assessment with dynamic susceptibility contrast MR imaging. Radiology 1999;210:558–562.
11.
Lin DD, Kleinman JT, Wityk RJ, et al. Crossed cerebellar diaschisis in acute stroke detected by dynamic susceptibility contrast MR perfusion imaging. AJNR Am J Neuroradiol 2009;30:710–715.
12.
Madai VI, Altaner A, Stengl KL, et al. Crossed cerebellar diaschisis after stroke: can perfusion-weighted MRI show functional inactivation? J Cereb Blood Flow Metab 2011;31:1493–1500.
13.
Chalela JA, Alsop DC, Gonzalez-Atavales JB, Maldjian JA, Kasner SE, Detre JA. Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 2000;31:680–687.
14.
Kang KM, Sohn CH, Choi SH, et al. Detection of crossed cerebellar diaschisis in hyperacute ischemic stroke using arterial spin-labeled MR imaging. PLoS One 2017;12:e0173971.
15.
Slessarev M, Han J, Mardimae A, et al. Prospective targeting and control of end-tidal CO2 and O2 concentrations. J Physiol 2007;581:1207–1219.
16.
van Niftrik CHB, Piccirelli M, Bozinov O, et al. Iterative analysis of cerebrovascular reactivity dynamic response by temporal decomposition. Brain Behav 2017;7:e00705.
17.
Fierstra J, Sobczyk O, Battisti-Charbonney A, et al. Measuring cerebrovascular reactivity: what stimulus to use? J Physiol 2013;591:5809–5821.
18.
Mutch WA, Mandell DM, Fisher JA, et al. Approaches to brain stress testing: BOLD magnetic resonance imaging with computer-controlled delivery of carbon dioxide. PLoS One 2012;7:e47443.
19.
Fierstra J, van Niftrik C, Warnock G, et al. Staging hemodynamic failure with blood oxygen-level–dependent functional magnetic resonance imaging cerebrovascular reactivity. Stroke 2018;49:621–629.
20.
Buxton RB. The physics of functional magnetic resonance imaging (fMRI). Rep Prog Phys 2013;76:096601.
21.
Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990;87:9868–9872.
22.
Strother MK, Buckingham C, Faraco CC, et al. Crossed cerebellar diaschisis after stroke identified noninvasively with cerebral blood flow-weighted arterial spin labeling MRI. Eur J Radiol 2016;85:136–142.
23.
Alpert NM, Eriksson L, Chang JY, et al. Strategy for the measurement of regional cerebral blood flow using short-lived tracers and emission tomography. J Cereb Blood Flow Metab 1984;4:28–34.
24.
Treyer V, Jobin M, Burger C, Teneggi V, Buck A. Quantitative cerebral H2(15)O perfusion PET without arterial blood sampling, a method based on washout rate. Eur J Nucl Med Mol Imaging 2003;30:572–580.
25.
Serrati C, Marchal G, Rioux P, et al. Contralateral cerebellar hypometabolism: a predictor for stroke outcome? J Neurol Neurosurg Psychiatry 1994;57:174–179.
26.
Dani KA, Santosh C, Brennan D, Hadley DM, Muir KW. Crossed cerebellar diaschisis: insights into oxygen challenge MRI. J Cereb Blood Flow Metab 2012;32:2114–2117.
27.
van Niftrik CH, Piccirelli M, Bozinov O, et al. Fine tuning breath-hold-based cerebrovascular reactivity analysis models. Brain Behav 2016;6:e00426.
28.
Sommer WH, Bollwein C, Thierfelder KM, et al. Crossed cerebellar diaschisis in patients with acute middle cerebral artery infarction: occurrence and perfusion characteristics. J Cereb Blood Flow Metab 2016;36:743–754.
29.
Kunz WG, Sommer WH, Hohne C, et al. Crossed cerebellar diaschisis in acute ischemic stroke: impact on morphologic and functional outcome. J Cereb Blood Flow Metab 2017;27:3615–3624.
30.
Nocun A, Wojczal J, Szczepanska-Szerej H, Wilczynski M, Chrapko B. Quantitative evaluation of crossed cerebellar diaschisis, using voxel-based analysis of Tc-99m ECD brain SPECT. Nucl Med Rev Cent East Eur 2013;16:31–34.
31.
Infeld B, Davis SM, Lichtenstein M, Mitchell PJ, Hopper JL. Crossed cerebellar diaschisis and brain recovery after stroke. Stroke 1995;26:90–95.
32.
Cicirata F, Zappala A, Serapide MF, Parenti R, Panto MR, Paz C. Different pontine projections to the two sides of the cerebellum. Brain Res Brain Res Rev 2005;49:280–294.
33.
Kultas-Ilinsky K, Ilinsky IA, Verney C. Glutamic acid decarboxylase isoform 65 immunoreactivity in the motor thalamus of humans and monkeys: gamma-aminobutyric acidergic connections and nuclear delineations. J Comp Neurol 2011;519:2811–2837.
34.
Bogsrud TV, Rootwelt K, Russell D, Nyberg-Hansen R. Acetazolamide effect on cerebellar blood flow in crossed cerebral-cerebellar diaschisis. Stroke 1990;21:52–55.
35.
Ishii K, Kanno I, Uemura K, et al. Comparison of carbon dioxide responsiveness of cerebellar blood flow between affected and unaffected sides with crossed cerebellar diaschisis. Stroke 1994;25:826–830.
36.
Ito H, Kanno I, Shimosegawa E, Tamura H, Okane K, Hatazawa J. Hemodynamic changes during neural deactivation in human brain: a positron emission tomography study of crossed cerebellar diaschisis. Ann Nucl Med 2002;16:249–254.
37.
Di Piero V, Chollet F, Dolan RJ, Thomas DJ, Frackowiak R. The functional nature of cerebellar diaschisis. Stroke 1990;21:1365–1369.
38.
Pantano P, Lenzi GL, Guidetti B, et al. Crossed cerebellar diaschisis in patients with cerebral ischemia assessed by SPECT and 123I-HIPDM. Eur Neurol 1987;27:142–148.
39.
Fierstra J, Maclean DB, Fisher JA, et al. Surgical revascularization reverses cerebral cortical thinning in patients with severe cerebrovascular steno-occlusive disease. Stroke 2011;42:1631–1637.
40.
Jussen D, Zdunczyk A, Schmidt S, et al. Motor plasticity after extra-intracranial bypass surgery in occlusive cerebrovascular disease. Neurology 2016;87:27–35.
41.
Matsumoto Y, Oikawa K, Nomura JI, et al. Optimal brain 99mtc-ethyl cysteinate dimer SPECT imaging and analysis to detect misery perfusion on 15O PET imaging in patients with chronic occlusive disease of unilateral major cerebral artery. Clin Nucl Med 2017;42:499–505.
42.
Chung JW, Park SH, Kim N, et al. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification and vascular territory of ischemic stroke lesions diagnosed by diffusion-weighted imaging. J Am Heart Assoc 2014;3:e001119.
Letters to the Editor
18 March 2019
Author response: BOLD cerebrovascular reactivity as a novel marker for crossed cerebellar diaschisis
Christiaan H.B. van Niftrik, Neurosurgical Resident| Department of Neurosurgery, University Hospital Zurich, University of Zurich (Zurich, Switzerland)
Martina Sebök, Neurosurgical Resident| Department of Neurosurgery, University Hospital Zurich, University of Zurich (Zurich, Switzerland)
Jorn Fierstra, Neurosurgeon| Department of Neurosurgery, University Hospital Zurich, University of Zurich (Zurich, Switzerland)

We kindly thank Drs. Reidler and Kunz for their insightful comments regarding our paper.1 The main objective was to study BOLD-CVR for CCD detection. In this regard, worse clinical outcome in the CCD(+) group should indeed be interpreted with caution. Ideally, this association needs to be further investigated in a uniform stroke cohort with sequential follow-up studies.

We deliberately did not comment on supratentorial stroke volume, since it is an inexact measurement and does not say anything about the infarct location.2 Besides, the concept that stroke volume is highly associated with presence of CCD in the acute phase remains debatable, as the studies mentioned in the readers’ comment appeared to be in disagreement.3,4 Nevertheless, we agree that stroke location would be a better variable for an adjusted analysis.

The statement made by Drs. Reidler and Kunz about "inferior cerebrovascular response indicating more severe supratentorial lesions" is, however, erroneous. We have only shown the presence of more impaired supratentorial BOLD-CVR in the CCD(+) group. This finding has led us to believe that hemodynamic alterations may also cause CCD rather than a functional disruption alone. In general, BOLD imaging enables investigations on resting-state functional connectivity and the influence of CCD-induced altered metabolism in stroke patients.5

References

  1. Sebok M, van Niftrik CHB, Piccirelli M, et al. BOLD cerebrovascular reactivity as a novel marker for crossed cerebellar diaschisis. Neurology 2018;91:e1328–e1337.
  2. Cassidy JM, Tran G, Quinlan EB, Cramer SC. Neuroimaging identifies patients most likely to respond to a restorative stroke therapy. Stroke 2018;49:433–438.
  3. Kang KM, Sohn CH, Choi SH, Jung KH, Yoo RE, Yun TJ et al. Detection of crossed cerebellar diaschisis in hyperacute ischemic stroke using arterial spin-labeled MR imaging. PloS One 2017; 12:e0173971.
  4. Kunz WG, Sommer WH, Höhne C, et al. Crossed cerebellar diaschisis in acute ischemic stroke: Impact on morphologic and functional outcome. J Cereb Blood Flow Metab 2017;37:3615–3624.
  5. Van Niftrik CHB, Sebok M, Muscas G, et al. Characterizing ipsilateral thalamic diaschisis in symptomatic cerebrovascular steno-occlusive patients. J Cereb Blood Flow Metab 2019;12:271678x19830532.

Footnote

For disclosures, please contact the editorial office at [email protected].

17 September 2018
Reader response: BOLD cerebrovascular reactivity as a novel marker for crossed cerebellar diaschisis
Paul Reidler, Radiology Resident| Department of Radiology, University Hospital, LMU Munich
Wolfgang G. Kunz, Assistant Professor of Radiology| Department of Radiology, University Hospital, LMU Munich

We read with great interest the article by Sebök et al. on the detection of crossed cerebellar diaschisis (CCD) in subacute and chronic stroke using BOLD-MRI. [1] They observed that patients with signs of CCD had poorer neurologic function at baseline and at 3 months. However, as adjusted analysis is lacking, it remains unclear whether CCD was the cause or consequence of poor outcomes.

The phenomenon of CCD, especially in the acute phase, is highly associated with large-volume supratentorial stroke. [2,3] Acute CCD had no independent impact on outcome and may be an epiphenomenon of large-volume strokes. [2] Correlations of chronic CCD with worse outcome have been reported, yet adjustments were not made for confounders. [4,5] In the current study, inferior cerebrovascular response indicated more severe supratentorial lesions in the CCD+ group, yet lesion volumes were not specified. [1] As lesion volume and distribution affect outcome, group comparisons should be interpreted with caution concerning a CCD-outcome relationship. The final infarct size and location would provide additional insight on this matter.

Interestingly, CCD has been linked to BOLD signal change, a measure of neuronal metabolism and activity. This is encouraging for future studies relating resting state functional connectivity and CCD status.

  1. Sebök M, van Niftrik CHB, Piccirelli M, et al. BOLD cerebrovascular reactivity as a novel marker for crossed cerebellar diaschisis. Neurology Epub 2018 Sep 5.
  2. Kunz WG, Sommer WH, Hohne C, et al. Crossed cerebellar diaschisis in acute ischemic stroke: Impact on morphologic and functional outcome. J Cereb Blood Flow Metab 2017;37:3615-3624.
  3. Kang KM, Sohn CH, Choi SH, et al. Detection of crossed cerebellar diaschisis in hyperacute ischemic stroke using arterial spin-labeled MR imaging. PLoS One 2017;12:e0173971.
  4. Sobesky J, Thiel A, Ghaemi M, et al. Crossed cerebellar diaschisis in acute human stroke: a PET study of serial changes and response to supratentorial reperfusion. J Cereb Blood Flow Metab 2005;25:1685-1691.
  5. Takasawa M, Watanabe M, Yamamoto S, et al. Prognostic value of subacute crossed cerebellar diaschisis: single-photon emission CT study in patients with middle cerebral artery territory infarct. AJNR Am J Neuroradiol 2002;23:189-193.

For disclosures, please contact the editorial office at [email protected].

Information & Authors

Information

Published In

Neurology®
Volume 91Number 14October 2, 2018
Pages: e1328-e1337
PubMed: 30185447

Publication History

Received: March 1, 2018
Accepted: July 2, 2018
Published online: September 5, 2018
Published in print: October 2, 2018

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

This work was funded by 2 personal grants obtained by Dr. Jorn Fierstra (Zurich University Forschungskredit; Postdoc 2016, FK-16-040 & Swiss Cancer League, KFS-3975-08-2016-R).

Authors

Affiliations & Disclosures

Martina Sebök, MD*
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Christiaan H.B. van Niftrik, MD*
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Marco Piccirelli, PhD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Oliver Bozinov, MD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Susanne Wegener, MD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Amgen, Speakers honoraria
Editorial Boards:
1.
Stroke Review Editor for
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Research Support by Boeringer Ingelheim
Research Support, Government Entities:
1.
1) Swiss National Science Foundation ID: PP00P3_170683 role: PI; (2017-2021)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1) UZH Filling the Gap fondation: role: PI (2016-2017) 2) Swiss heart Foundation: role: Co-PI (2017-2019)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Giuseppe Esposito, MD, PhD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Athina Pangalu, MD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Antonios Valavanis, MD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Neuroradiology, editorial board member, since 2001 Journal of interventional and therapeutic Neuroradiology, corresponding editor
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Alfred Buck, MD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
1 Medrad, 5 years 2 Automatic radioactivity injector
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Andreas R. Luft, MD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
(1) Boehringer Ingelheim (2) Pfizer (3) Hocoma AG, Volketswil, Switzerland (4) Amgen
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Daiichi Sankyo, conference travel to ESOC 2017
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
(1) cereneo Center for Neurology and Rehabilitation, Medical Director, 4 years
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Swiss National Science Foundation
Research Support, Academic Entities:
1.
(1) CRPP Program, University of Zurich
Research Support, Foundations and Societies:
1.
(1) P&K P?hringer Foundation (2) McDonnell Foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
- cereneo Center for Neurology and Rehabilitation, 2016
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Luca Regli, MD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jorn Fierstra, MD, PhD
From the Department of Neurosurgery (M.S., C.H.B.v.N., O.B., G.E., L.R., J.F.), Clinical Neuroscience Center (M.S., C.H.B.v.N., M.P., O.B., S.W., G.E., A.P., A.V., A.R.L., L.R., J.F.), and Departments of Neuroradiology (M.P., A.P., A.V.), Neurology (S.W., A.R.L.), and Nuclear Medicine (A.B.), University Hospital Zurich, University of Zurich, Switzerland.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Fierstra [email protected]
*
These authors contributed equally to this work.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Dr. Sebök: study concept and design, acquisition of data, analysis and interpretation, constructed the manuscript. Dr. van Niftrik: patient selection, study concept and design, acquisition of data, analysis and interpretation, constructed the manuscript. Dr. Piccirelli: acquisition of data, analysis and interpretation, critical revision of the manuscript for important intellectual content. Dr. Bozinov: patient selection, critical revision of the manuscript for important intellectual content, study supervision. Prof. Wegener: critical revision of the manuscript for important intellectual content. Dr. Esposito: critical revision of the manuscript for important intellectual content. Dr. Pangalu: analysis and interpretation, critical revision of the manuscript for important intellectual content. Prof. Valavanis: critical revision of the manuscript for important intellectual content. Prof. Buck: acquisition of data, analysis and interpretation, critical revision of the manuscript for important intellectual content. Prof. Luft: critical revision of the manuscript for important intellectual content. Prof. Regli: patient selection, critical revision of the manuscript for important intellectual content, study supervision. Dr. Fierstra: patient selection, study concept and design, acquisition of data, analysis and interpretation, study supervision.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. White matter abnormalities in aneurysmal and angiographically negative subarachnoid hemorrhage: A diffusion kurtosis imaging study, NeuroImage: Clinical, 43, (103662), (2024).https://doi.org/10.1016/j.nicl.2024.103662
    Crossref
  2. Case report: Multiple disconnection patterns revealed by a multi-modal analysis explained behavior after a focal frontal damage, Frontiers in Neurology, 14, (2023).https://doi.org/10.3389/fneur.2023.1142734
    Crossref
  3. Hemodynamic Failure Staging With Blood Oxygenation Level–Dependent Cerebrovascular Reactivity and Acetazolamide‐Challenged ( 15 O‐)H 2 O‐Positron Emission Tomography Across Individual Cerebrovascular Territories , Journal of the American Heart Association, 12, 24, (2023).https://doi.org/10.1161/JAHA.123.029491
    Crossref
  4. Heterogeneous motor BOLD-fMRI responses in brain areas exhibiting negative BOLD cerebrovascular reactivity indicate that steal phenomenon does not always result from exhausted cerebrovascular reserve capacity, Magnetic Resonance Imaging, 103, (124-130), (2023).https://doi.org/10.1016/j.mri.2023.07.010
    Crossref
  5. Research Applications of Positron Emission Tomography/Magnetic Resonance (PET/MR) Imaging in Cerebrovascular Diseases, PET/MR: Functional and Molecular Imaging of Neurological Diseases and Neurosciences, (265-296), (2023).https://doi.org/10.1007/978-981-19-9902-4_12
    Crossref
  6. Neurovascular Uncoupling in Functional MRI, Functional Neuroradiology, (511-520), (2023).https://doi.org/10.1007/978-3-031-10909-6_23
    Crossref
  7. Editorial for “Altered Callosal Morphology and Connectivity in Asymptomatic Carotid Stenosis”, Journal of Magnetic Resonance Imaging, 59, 3, (1008-1009), (2023).https://doi.org/10.1002/jmri.28867
    Crossref
  8. Diaschisis Profiles in the Cerebellar Response to Hemodynamic Stimuli: Insights From Dynamic Measurement of Cerebrovascular Reactivity to Identify Occult and Transient Maxima, Journal of Magnetic Resonance Imaging, 58, 5, (1462-1469), (2023).https://doi.org/10.1002/jmri.28648
    Crossref
  9. Editorial for “Diaschisis Profiles in the Cerebellar Response to Hemodynamic Stimuli: Insights From Dynamic Measurement of Cerebrovascular Reactivity to Identify Occult and Transient Maxima”, Journal of Magnetic Resonance Imaging, 58, 5, (1470-1471), (2023).https://doi.org/10.1002/jmri.28646
    Crossref
  10. More pronounced hemodynamic alterations in patients with brain arteriovenous malformation–associated epilepsy, Neurosurgical Focus, 53, 1, (E4), (2022).https://doi.org/10.3171/2022.4.FOCUS22117
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

View Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share